English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The objective of this study was to estimate the economic impact of the introduction of DuoResp ® Spiromax ® , budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia.

clinicoeconomics and outcomes research

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>&reg; </sup>compared with Turbuhaler<sup>&reg; </sup>in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax^®compared with Turbuhaler^®in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain